BioCentury | Jan 23, 2018
Distillery Therapeutics

Cancer

...channel blocker, for myasthenic syndromes and have it in Phase II/III testing for myasthenia gravis. Blue Ash Therapeutics LLC...
BioCentury | May 13, 2013
Product Development

An association for dissociation

...potassium channel blocker in Phase III testing for arrhythmia. Forest licensed azimilide in 2011 from Blue Ash Therapeutics LLC...
...a larger company better able to market it in primary care. Companies and Institutions Mentioned Blue Ash Therapeutics LLC...
BioCentury | Apr 25, 2011
Finance

Highlights of weekly biotech stock moves

...last week after reporting earnings and receiving exclusive, worldwide rights to antiarrhythmic candidate azimilide from Blue Ash Therapeutics LLC...
BioCentury | Apr 25, 2011
Company News

Blue Ash Therapeutics, Forest Laboratories deal

...eligible for royalties. Forest is responsible for all future development and commercialization costs and activities. Blue Ash Therapeutics LLC...
BioCentury | Apr 20, 2011
Company News

Azimilide finds its way to Forest

Blue Ash Therapeutics LLC (Cincinnati, Ohio) granted Forest Laboratories Inc. (NYSE:FRX) exclusive, worldwide rights to antiarrhythmic candidate azimilide . Last year, Blue Ash licensed the potassium channel blocker from Warner Chilcott plc (NASDAQ:WCRX), which acquired the...
Items per page:
1 - 5 of 5
BioCentury | Jan 23, 2018
Distillery Therapeutics

Cancer

...channel blocker, for myasthenic syndromes and have it in Phase II/III testing for myasthenia gravis. Blue Ash Therapeutics LLC...
BioCentury | May 13, 2013
Product Development

An association for dissociation

...potassium channel blocker in Phase III testing for arrhythmia. Forest licensed azimilide in 2011 from Blue Ash Therapeutics LLC...
...a larger company better able to market it in primary care. Companies and Institutions Mentioned Blue Ash Therapeutics LLC...
BioCentury | Apr 25, 2011
Finance

Highlights of weekly biotech stock moves

...last week after reporting earnings and receiving exclusive, worldwide rights to antiarrhythmic candidate azimilide from Blue Ash Therapeutics LLC...
BioCentury | Apr 25, 2011
Company News

Blue Ash Therapeutics, Forest Laboratories deal

...eligible for royalties. Forest is responsible for all future development and commercialization costs and activities. Blue Ash Therapeutics LLC...
BioCentury | Apr 20, 2011
Company News

Azimilide finds its way to Forest

Blue Ash Therapeutics LLC (Cincinnati, Ohio) granted Forest Laboratories Inc. (NYSE:FRX) exclusive, worldwide rights to antiarrhythmic candidate azimilide . Last year, Blue Ash licensed the potassium channel blocker from Warner Chilcott plc (NASDAQ:WCRX), which acquired the...
Items per page:
1 - 5 of 5